Since the discovery of calcitonin gene-related peptide (CGRP) as a key driver of migraine pain, a new class of targeted therapies has transformed treatment. In 2026, Nurtec (rimegepant), Ubrelvy (ubrogepant), and Aimovig (erenumab) lead the pack — each with distinct advantages depending on whether you need acute relief, prevention, or both.
The CGRP Revolution: Gepants vs. Monoclonal Antibodies
Both drug classes target the CGRP pathway, but through different mechanisms:
- Gepants (Nurtec, Ubrelvy) are small-molecule CGRP receptor blockers taken orally. They can work as acute treatments and, in Nurtec's case, as daily preventives.
- Monoclonal antibodies (Aimovig, Emgality, Ajovy) are large proteins injected monthly or quarterly that bind to CGRP itself (or its receptor). They are preventive-only — they don't stop an attack in progress.
Head-to-Head Comparison
| Feature | Nurtec (Rimegepant) | Ubrelvy (Ubrogepant) | Aimovig (Erenumab) |
|---|---|---|---|
| Drug class | Oral gepant | Oral gepant | Injectable mAb |
| Use | Acute AND preventive | Acute only | Preventive only |
| Dose | 75 mg as needed or daily | 50–100 mg as needed | 70–140 mg monthly injection |
| Onset | 1–2 hours | ~1 hour | 2–4 weeks for full effect |
| Common side effects | Nausea, fatigue, constipation | Nausea, dizziness | Injection site reactions, constipation |
| MOH risk | Low (may not cause MOH) | Low | N/A (preventive) |
| Cost (brand/month) | $800–$1,000 | $800–$1,000 | $800–$1,000 |
Acute vs. Preventive: Which Do You Need?
- Under 4 migraines/month: An acute-only treatment like Ubrelvy may suffice
- 4–8 migraines/month: Nurtec's dual acute+preventive approval is ideal — one medication for both purposes
- 8+ migraines/month: A dedicated preventive (Aimovig, Emgality, or Ajovy) plus an acute treatment is typically recommended
Other CGRP Preventive Injections
- Emgality (galcanezumab): Monthly injection, targets CGRP ligand. Similar efficacy to Aimovig. Also approved for cluster headache.
- Ajovy (fremanezumab): Monthly or quarterly injection option — the only CGRP mAb with a quarterly dosing schedule, ideal for patients who want fewer injections.
Insurance and Cost Reality
At $800–$1,000/month retail, insurance coverage is critical. Most insurers require:
- Prior authorization: Proof that older medications (triptans, topiramate, beta-blockers) failed
- Step therapy: You may need to try 2–3 cheaper medications first
- Quantity limits: Many plans limit gepant prescriptions to 8 doses/month
Manufacturer copay cards can reduce brand costs to $0–$10/month for commercially insured patients. Generic gepants are expected by 2027–2028.
How to Choose
- Want one pill for everything? Nurtec (acute + preventive)
- Need fast acute relief only? Ubrelvy
- Want set-it-and-forget-it prevention? Aimovig or Ajovy (quarterly)
- Hate injections? Nurtec or Ubrelvy (oral)
Always discuss your migraine pattern, insurance coverage, and preferences with a neurologist or headache specialist to find the best fit.
This article is for informational purposes only. Always consult your healthcare provider before starting or changing migraine treatment.